A Randomized Phase III Study of Patients With Advanced Gastric Adenocarcinoma Without Progression After Six Cycles of XELOX (Capecitabine Plus Oxaliplatin) Followed by Capecitabine Maintenance or Clinical Observation

PURPOSE: Oxaliplatin, a component of the capecitabine plus oxaliplatin (XELOX) regimen, has a more favorable toxicity profile than cisplatin in patients with advanced gastric cancer (GC). However, oxaliplatin can induce sensory neuropathy and cumulative, dose-related toxicities. Thus, the capecitabi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Guk Jin, Kim, Hyunho, Cho, Sung Shim, Park, Hyung Soon, An, Ho Jung, Woo, In Sook, Byun, Jae Ho, Hong, Ji Hyung, Ko, Yoon Ho, Sun, Der Sheng, Won, Hye Sung, Jin, Jong Youl, Park, Ji Chan, Kim, In-Ho, Roh, Sang Young, Shim, Byoung Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Gastric Cancer Association 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154142/
https://www.ncbi.nlm.nih.gov/pubmed/37129155
http://dx.doi.org/10.5230/jgc.2023.23.e16

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154142/
https://www.ncbi.nlm.nih.gov/pubmed/37129155
http://dx.doi.org/10.5230/jgc.2023.23.e16

Ejemplares similares